GlobeNewsWire -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and National Principal Investigator of the Company’s U.S. Phase II IMPACT-DCM clinical trial, will provide an overview of Aastrom’s cardiovascular programs at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco, California. Dr. Patel’s presentation is part of the session entitled “Session III -- Changing the Course of End-Stage Chronic Heart Failure,” and will take place at approximately 3:17 p.m. (PDT) today, September 22, 2009.
